Keep pulling the thread on Cloud Code.
Hippocratic's AI successfully reached 270 out of 1,700 targeted patients for lung cancer screenings after previous outreach attempts via text, voicemail, and nurses had failed.
All 270 patients reached by Hippocratic's AI in a lung cancer screening campaign agreed to come in for the screening.
To incentivize payers to establish electronic connectivity, Mel's company's go-to-market strategy involved making up to 8,000 AI-driven phone calls per day to payers, creating an operational burden on them.
Hippocratic's AI agents have achieved a 99.9% safety level across more than 11 million patient calls.
Mel believes AI has the potential to eliminate the estimated $500 billion in administrative waste generated by payer-provider communications in the U.S. healthcare system.
Artera's AI platform helps doctors personalize therapy for cancer patients by predicting patient outcomes over a 10 to 20-year horizon.
Artera's AI platform for personalizing cancer therapy aims to reduce the amount of treatment given to patients, thereby lowering costs and decreasing unnecessary side effects.
In a campaign with a large hospital system in Chicago, Hippocratic's AI contacted 1,700 'forgotten' patients for lung cancer screenings.
A core product strategy for Mel's prior authorization company is that their solution must not change or disrupt the existing workflow of the prescribing physician.
Anand from Hippocratic has observed that middle management in healthcare organizations is often more resistant to adopting their AI technology than senior management.
Before launching a new use case, Hippocratic conducts clinical testing on its AI agents over a sample of 1,000 calls.
According to Andre from Artera, the five major barriers to adoption for new healthcare technologies are data collection, evidence publication, regulatory hurdles like FDA clearance and HIPAA compliance, reimbursement, and clinical workflow integration.